I would say that the gap is now closer with the CETA and what we're trying to do with CETA. We're looking at a two-year gap there. Maybe with the U.S. I think it's still a little longer, because there are additional things, such as if it's a pediatric product or an orphan drug. There are some specificities. Compared to Europe, I would say that we're much closer as far as Europe is concerned.
In this particular TPP, I'm not really clear on where we're going to land, but my understanding is that we're moving in the right direction. I want to encourage it so that we do keep getting better and better and that we're closer to the U.S. regime, because at the end of the day, people always ask that question: why does the U.S. still manage to get international investment, not just from within the U.S.? In this development, a lot of the European countries also put money and research into the Boston clusters and the California clusters. IP is a big part of that. It's not the only component, but it's a big part.